Explore BPS Bioscience’s services for bispecific antibodies and BiTEs. Discover our solutions for developing and optimizing bispecific T-cell engager therapies.
These are capable of connecting any kind of cytotoxic T cell to a cancer cell, independently of T-cell receptor specificity, costimulation, or peptide antigen presentation. Here, we review the principle of a new class of bispecific antibodies called BiTE (for "bispecific T-cell engager...
et al. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol. Immunother. 59, 1197–1209 (2010). CAS PubMed Google Scholar Ahmed, M., Cheng, M., Cheung...
Einsele, H. et al. The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types.Cancer126, 3192–3201 (2020). ArticleCASPubMedGoogle Scholar Suurs, F. V., Lub-de Hooge, M. N., de Vries, E. G. E. & de ...
The schematic representation of structure and mechanism of action of canonical bispecific T-cell engager (BiTE). mAb: Monoclonal antibody; VH: Heavy chain variable region; VL: Light chain variable region; TAA: Tumor-associated antigen Full size image ...
Bispecific T-cell engager molecules (BiTEs) constitute a class of bispecific single-chain antibodies for the polyclonal activation and redirection of cytot... E Wolf,R Hofmeister,P Kufer,... - 《Drug Discovery Today》 被引量: 239发表: 2005年 Immunotherapy of lymphoma and leukemia with T-cell...
Bispecific T-cell engager (BiTE) antibodies represent a novel therapeutic option for patients with multiple myeloma (MM). BiTE antibodies lack Fc region, and have variable domain only, they can simultaneously bind to two different epitopes i.e. cluster of differentiation 3 (CD3) molecules on tumo...
We developed a bispecific T-cell engager (BiTE) targeting BCMA and CD3ε (BI 836909) and studied its therapeutic impacts on MM. BI 836909 induced selective lysis of BCMA- positive MM cells, activation of T cells, release of cytokines and T-cell proliferation; whereas BCMA-negative cells ...
Although numerous formats are currently in clinical development the only approved bispecific antibody fragment to date is blinatumomab (trade name Blincyto®) from Amgen. This is a bispecific T-cell engager or BiTE. BiTEs are constructed by genetic fusion of two single chain variable fragments (scF...
Bispecific antibodycan simultaneously bind to two different antigens or two different epitopes on one single antigen.(Ragni, 2019;Wu et al., 2015). BispecificT cellEngager (BiTE) is the most established class of bispecific antiboy that could bridge target tumor cells and effector T cells, resul...